Shares of NeurogesX Inc. plunged Thursday after the firm said a confirmatory Phase III study of its capsaicin dermal patch NGX-4010 missed its primary endpoint of providing statistically significant benefit in treating peripheral neuropathic pain in patients with HIV infection. (BioWorld Today)